Dasatinib

This medication produced by Lucius Pharmaceuticals, which shares the same active ingredients and therapeutic efficacy as the original drug, provides patients with a more cost-effective treatment option.

Below is a brief overview of the key information on dasatinib:

Main Ingredient

The main active ingredient is dasatinib.

Target Population

Indicated for adult and pediatric patients aged 1 year and older with confirmed Philadelphia chromosome-positive chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL).

Dosage and Administration

For adults: The usual oral dose is 100 mg once daily for the chronic phase; for the accelerated phase or ALL, the dose is 140 mg once daily.

For pediatric patients: The dose is determined based on body weight, administered once daily.

Reference article: Dosage and Administration of Dasatinib

Use in Special Populations

Men and women of reproductive age must use effective contraception.

Lactating women are contraindicated from using this medication.

Elderly patients require close monitoring for relevant adverse reactions.

Patients with hepatic impairment need dosage adjustment.

Drug Overdose

Overdose may lead to severe myelosuppression and bleeding. Close monitoring and supportive treatment are required.

Storage

Store at room temperature between 20°C and 25°C, and protect from moisture.

Pharmacokinetics

Dasatinib is rapidly absorbed after oral administration. It is mainly metabolized by the CYP3A4 enzyme, with a half-life of approximately 3-5 hours, and is primarily excreted via feces.

FDA，2024.07